BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $16.56 Consensus Target Price from Brokerages

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have been given a consensus recommendation of “Moderate Buy” by the nine research firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $16.56.

A number of brokerages have issued reports on BCRX. Barclays boosted their price objective on shares of BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the company an “equal weight” rating in a research report on Wednesday, May 7th. Wedbush began coverage on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. They set an “outperform” rating and a $15.00 price objective on the stock. Cantor Fitzgerald began coverage on shares of BioCryst Pharmaceuticals in a research report on Tuesday, April 29th. They set an “overweight” rating and a $20.00 price objective on the stock. Royal Bank of Canada reissued an “outperform” rating and set a $13.00 price objective (up from $11.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 6th. Finally, Wall Street Zen raised shares of BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, May 22nd.

BioCryst Pharmaceuticals Stock Down 1.4%

Shares of NASDAQ BCRX opened at $10.73 on Wednesday. BioCryst Pharmaceuticals has a 52 week low of $5.92 and a 52 week high of $11.11. The firm’s fifty day moving average is $8.66 and its 200 day moving average is $8.15. The company has a market cap of $2.25 billion, a price-to-earnings ratio of -17.59 and a beta of 1.08.

Institutional Trading of BioCryst Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of BCRX. Millennium Management LLC grew its position in shares of BioCryst Pharmaceuticals by 382.6% in the 1st quarter. Millennium Management LLC now owns 3,812,874 shares of the biotechnology company’s stock worth $28,597,000 after buying an additional 3,022,769 shares during the period. Vanguard Group Inc. boosted its stake in BioCryst Pharmaceuticals by 7.8% in the 4th quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company’s stock worth $164,616,000 after purchasing an additional 1,583,826 shares in the last quarter. Eversept Partners LP boosted its stake in BioCryst Pharmaceuticals by 269.9% in the 4th quarter. Eversept Partners LP now owns 1,980,312 shares of the biotechnology company’s stock worth $14,892,000 after purchasing an additional 1,444,907 shares in the last quarter. Nuveen LLC bought a new position in BioCryst Pharmaceuticals in the 1st quarter worth about $10,677,000. Finally, Jupiter Asset Management Ltd. boosted its stake in BioCryst Pharmaceuticals by 82.4% in the 1st quarter. Jupiter Asset Management Ltd. now owns 2,148,969 shares of the biotechnology company’s stock worth $16,117,000 after purchasing an additional 971,040 shares in the last quarter. 85.88% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.